Abstract: Angiogenesis is the main pathologic change in many important ocular diseases，and vascular endothelial growth factor (VEGF) is the crucial angiogenic stimulator. In recent years, soluble vascular endothelial growth factor receptor-2 (sVEGFR-2) has been proved to be a native inhibitor of the angiogenesis and signal transduction pathways induced by VEGF. Studies indicated that sVEGFR2 had intimate connection with the occurance and progression of ocular angiogenesis, and could be regarded as an inhibitory factor as well as surrogate marker of neovascular eye diseases, which implies a potential clinical practice. This review focuses on the recent advances of the inhibitory effects of sVEGFR-2 on the ocular neovascularization.